Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

16.98 -0.74 (-4.18%)
Streaming Delayed Price Updated: 10:15 AM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
From HUTCHMED (China) Limited
Via GlobeNewswire
AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Sarepta Therapeutics Stock Showing Rising Relative Strength
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — 
From HUTCHMED (China) Limited
Via GlobeNewswire
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may... 
Via Talk Markets
Hutchmed's Candidate Achieves Main Goal In China's Rare Blood Disorder Study
HUTCHMED (China) Limited's (NASDAQ: ​HCM) pivotal Phase 3 trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints... 
Via Benzinga
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Gainers Save Foods, Inc. (NASDAQ: SVFD) shares surged 76.6% to $1.13 in pre-market trading after gaining 15% on Friday. 
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning! 
Via InvestorPlace
Sohu.com, Cloudflare And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. HUTCHMED (China) Limited (NYSE: HCM) shares dipped 14.1% to... 
Via Benzinga
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list. 
Via Benzinga
Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are some big stocks recording gains in today’s session. American Superconductor Corporation (NASDAQ: AMSC)... 
Via Benzinga
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
From HUTCHMED (China) Limited
Via GlobeNewswire
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million. 
Via Benzinga
HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee 
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2023 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.